ONCOLOGY & IMMUNOLOGY

Our team has 30+ years of experience in the

fields of Oncology and Immune Oncology with extensive experience in transitioning from cellular drug discovery to xenograft and syngeneic tumor models

Our preclinical program for evaluation of test compounds on both in-vitro and in-vivo platforms, offers our clients a unique suite of technologies, scientific expertise and technical skills.

Each study is custom-designed to best meet individual client needs. Data analysis and summary reports are provided at the completion of each study

Assays and Endpoints

~Tumor growth delay

~Tumor growth inhibition

~ Metastasis

~ MTD

~Survival

~drug combination or adjuvant

Design approaches may be used to assess your compound for:

~Drug potency (IC50)

~Apoptosis

~Cell Cycle

~Biomarker

~Discovery/Screening

~Pathway Interrogation

~Therapeutic Combinations

~Tumor antigen testing

Models

Assays and Endpoints

Standard Models

~Subcutaneous Cell Line Xenograft

~Subcutaneous Patient Derived Xenograft

~Syngeneic Murine Models

~Tumorgenicity Studies

~Immuno-Oncology

Specialized Models

~Tumor Bearing PK/PD Studies

~SCID / Humanized mouse models

~GEMM

~Monotherapy, Immunotherapy

~ Combination Therapy Screening

Surgery;Stereotaxic

Orthotopic

~Mammary Fat Pad

~Prostate

~Brain metastatic and orthotopic

~Renal Capsule

ONCOLOGY & IMMUNOLOGY

Assays and Endpoints

Assays and Endpoints

Assays and Endpoints

Models

Assays and Endpoints

Assays and Endpoints

This website uses cookies.